---
title: "Maze Therapeutics swaps 2,776,007 Frazier-held shares for pre-funded warrants"
url: "https://aibio.space/news/maze-therapeutics-swaps-2-776-007-frazier-held-shares-pre-funded/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2026-10-16"
section: "Financings"
tickers: "NASDAQ:MAZE"
source: "https://www.sec.gov/Archives/edgar/data/1842295/000119312526424067/d445364d8k.htm"
summary: "The exchange leaves Maze with 53,931,889 shares of common stock outstanding as of October 16, 2026."
---

By the aibio.space news desk.

Sources

- [Maze Therapeutics, Inc. 8-K (2026-10-16)](https://www.sec.gov/Archives/edgar/data/1842295/000119312526424067/d445364d8k.htm)

[MAZE](https://aibio.space/companies/maze-therapeutics/)

2026-10-16

# Maze Therapeutics swaps 2,776,007 Frazier-held shares for pre-funded warrants

Tickers [MAZE](https://aibio.space/companies/maze-therapeutics/)

The exchange leaves Maze with 53,931,889 shares of common stock outstanding as of October 16, 2026.

## Key facts

- **Company**: Maze Therapeutics, Inc. (NASDAQ: MAZE)

- **News type**: Financings

- **Primary source**: [Maze Therapeutics, Inc. 8-K (2026-10-16)](https://www.sec.gov/Archives/edgar/data/1842295/000119312526424067/d445364d8k.htm)

*A conference room set for a meeting. CC0, via rawpixel. The picture shows the field, not the companies named.*

Maze Therapeutics, Inc. (Nasdaq: [MAZE](https://aibio.space/companies/maze-therapeutics/)) entered into an exchange agreement on October 15, 2026 with four Frazier Life Sciences funds, which the filing calls the Exchanging Stockholder. Maze exchanged an aggregate of 2,776,007 shares of its common stock held by the funds for pre-funded warrants to buy the same number of shares. The warrants have an exercise price of $0.001 per share. A pre-funded warrant is a warrant whose price is almost entirely paid up front, so the holder pays only a nominal amount to receive the shares.

After the exchange, Maze had 53,931,889 shares of common stock outstanding as of October 16, 2026.

The warrants can be exercised at any time after issuance. The Exchanging Stockholder cannot exercise them if it would then beneficially own more than 9.99% of the outstanding common stock, subject to certain exceptions. Holders of the warrants have no right to vote the underlying shares except as Delaware law requires.

Maze said it will issue the warrants without registration under the Securities Act of 1933, relying on the exemption in Section 3(a)(9). The company reported the exchange in an 8-K filed October 16, 2026 under Items 1.01 and 3.02.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

MAZE

Maze Therapeutics, Inc.

NASDAQ · United States

Open the starter desk

## More in Financings

Financings

### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/)

Oct 29, 2026

Financings

### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/)

Oct 29, 2026

Financings

### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/)

Oct 29, 2026

---
Source page: https://aibio.space/news/maze-therapeutics-swaps-2-776-007-frazier-held-shares-pre-funded/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Maze Therapeutics swaps 2,776,007 Frazier-held shares for pre-funded warrants", 2026-10-16, https://aibio.space/news/maze-therapeutics-swaps-2-776-007-frazier-held-shares-pre-funded/